Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

Biocon Biologics, Viatris receive approval for cancer drug
Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - April 26, 2021 Category: Pharmaceuticals Source Type: news

Surgical technique may reduce positive margin rate in breast cancer patients with DCIS
(Wake Forest Baptist Medical Center) According to the American Cancer Society, a noninvasive breast cancer called ductal carcinoma in situ (DCIS) accounts for approximately one of every four new breast cancer cases in the United States. If left untreated, DCIS has the potential to evolve into invasive cancer, so many patients choose to have breast-conserving surgery or mastectomy after a diagnosis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 5, 2021 Category: Cancer & Oncology Source Type: news

Invasive Lobular Carcinoma: The Importance of This Subtype Invasive Lobular Carcinoma: The Importance of This Subtype
Get up-to-date on the latest research that has advanced our understanding of the pathology and management of this common subtype of breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 30, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

More accurate method to predict long term outcomes for pre-invasive breast cancer
(Queen Mary University of London) A study by Queen Mary University of London researchers, funded by Cancer Research UK, confirms the role of the oestrogen receptor biomarker in ductal carcinoma in situ and presents a new and more accurate method to predict long term outcomes for this pre-invasive stage of breast cancer. The study is published in Clinical Cancer Research. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2021 Category: International Medicine & Public Health Source Type: news

Biocon Biologics, Viatris Inc. get CHMP nod for Abevmy, a biosimilar to Avastin
Abevmy is abiosimilar to Roche's Avastin, prescribed for all indications including metastatic colorectal carcinoma, metastatic breast cancer, non-small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 1, 2021 Category: Pharmaceuticals Source Type: news

Scientists model a peculiar type of breast cancer
(Ecole Polytechnique F é d é rale de Lausanne) Scientists led by EPFL have developed a breakthrough in vivo model for invasive lobular carcinoma, a serious yet understudied type of breast cancer. The work will open up previously inaccessible study of the tumor's biology and help discover new therapies. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 22, 2021 Category: Biology Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Oncotarget: Heterogeneity of CEACAM5 in breast cancer
(Impact Journals LLC) Oncotarget recently published " Heterogeneity of CEACAM5 in breast cancer " which reported that Here, we examined a repository of 110 cryopreserved primary breast carcinomas by immunohistochemistry to assess the distribution of CEACAM5 in tumor subtypes. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 3, 2020 Category: International Medicine & Public Health Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Addition of Radiotherapy for DCIS Cuts Risk for Subsequent Cancer
FRIDAY, Oct. 16, 2020 -- For women with ductal carcinoma in situ (DCIS), the risk for developing subsequent ipsilateral in situ (iDCIS) and invasive breast cancer (iBC) is lower for those receiving breast-conserving surgery (BCS) and radiotherapy... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 16, 2020 Category: Pharmaceuticals Source Type: news

Study Helps Gauge Long-term Risks for Women With DCIS Study Helps Gauge Long-term Risks for Women With DCIS
New research helps clarify the long-term risk for invasive breast cancer in women with ductal carcinoma (DCIS) in situ who opt for breast-conserving surgery alone or with radiotherapy.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 8, 2020 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Genetic Test Spots High-Risk Invasive Lobular Carcinoma Genetic Test Spots High-Risk Invasive Lobular Carcinoma
A test that looks at the activity of 70 genes in breast tumors can help identify women with invasive lobular carcinoma (ILC) at high-risk of cancer recurrence or progression after surgery who may benefit from additional therapy, according to new research.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - October 6, 2020 Category: Pathology Tags: Pathology & Lab Medicine News Source Type: news

Radiation Plus Surgery May Be Best Against an Early Form of Breast Cancer
MONDAY, Oct. 5, 2020 -- Research following patients for nearly three decades finds that surgery plus radiation beats surgery alone for women with ductal carcinoma in situ (DCIS) -- a common, early form of breast cancer that can become invasive... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 5, 2020 Category: General Medicine Source Type: news

Ductal Carcinoma In Situ Tied to Threefold Higher Risk for Death
Risk for dying from breast cancer remains elevated 15 years after initial diagnosis (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 2, 2020 Category: Cancer & Oncology Tags: Family Medicine, Geriatrics, Gynecology, Internal Medicine, Oncology, Journal, Source Type: news

Ductal Carcinoma In Situ Tied to Threefold Higher Risk for Death
FRIDAY, Oct. 2, 2020 -- There is a threefold higher risk for dying of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to a study published online Sept. 16 in JAMA Network Open. Vasily Giannakeas, M.P.H., from... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 2, 2020 Category: Pharmaceuticals Source Type: news

Genetic test identifies invasive lobular carcinomas that are at high risk of recurring
(European Organisation for Research and Treatment of Cancer) New results to be presented at the 12th European Breast Cancer Conference show that a test, which looks at the activity of 70 genes in breast cancer tissue, is possible to use in the clinic to identify patients with invasive lobular carcinoma (ILC) that is at high risk of recurring and progressing. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 30, 2020 Category: Cancer & Oncology Source Type: news

Is an Early Form of Breast Cancer More Dangerous Than Thought?
TUESDAY, Sept. 22, 2020 -- Women diagnosed with an early, highly treatable form of breast cancer still face a higher-than-normal risk of eventually dying from the disease, a large new study finds. The study looked at women with ductal carcinoma in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 22, 2020 Category: General Medicine Source Type: news

Threefold Higher Risk for Breast Cancer Death With DCIS Threefold Higher Risk for Breast Cancer Death With DCIS
Compared to the general population, women with ductal carcinoma in situ (DCIS) were more than three times more likely to die from breast cancer; the risk was particularly high for Black women and young women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Media News - September 18, 2020 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 18 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemi c therapy. Based on this recommendation, a final decision regarding approval of Tecentriq in combination with Avastin in this disease setting, along with the full details of the approved indication, is expe...
Source: Roche Investor Update - September 18, 2020 Category: Pharmaceuticals Source Type: news

Women with DCIS have 3x the risk of breast cancer death
A new study adds weight to the belief that ductal carcinoma in situ (DCIS)...Read more on AuntMinnie.comRelated Reading: Delayed breast cancer surgery not tied to worse outcomes Preop MRI finds 11% more cancer in women with DCIS Years later, DCIS tied to more imaging but not anxiety Black women still at higher risk of breast cancer death Does imaging modality influence DCIS recurrence? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 17, 2020 Category: Radiology Source Type: news

Surgical Delays Not Life-Threatening in Early Breast Cancer
WEDNESDAY, Aug. 12, 2020 -- Surgical delays do not seem to be life-threatening for women with ductal carcinoma in situ (DCIS) or with early-stage estrogen receptor-positive (ER+) breast cancer, according to a study published online Aug. 6 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Investor Update - August 6, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer
Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-fr ee survival (PFS) for the initial (first-line) treatment of people with metastatic triple-negative breast cancer (TNBC), in the PD-L1-positive population. The data for the secondary endpoint of overall survival (OS) showed a negative trend, however, the study was not powered for the secondary endpoi...
Source: Roche Media News - August 6, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Investor Update - August 3, 2020 Category: Pharmaceuticals Source Type: news

Rozlytrek, Roche ’s first tumour-agnostic therapy, approved in Europe for people with NTRK fusion-positive solid tumours and for people with ROS1-positive advanced non-small cell lung cancer
             Basel, 03 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has granted conditional marketing authorisation for Rozlytrek®(entrectinib) for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, and who have not received a prior NTRK inhibitor, who have no satisfactory t...
Source: Roche Media News - August 3, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: The Golgi protein TMEM165 controls migration/invasion for carcinoma
(Impact Journals LLC) The cover for issue 28 of Oncotarget features Figure 5, 'TMEM165 expression levels alters N-linked glycosylation,' by Murali, et al., and reported that the TMEM165 protein was not detected in non-malignant matched breast tissues and was detected in invasive ductal breast carcinoma tissues by mass spectrometry. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 14, 2020 Category: International Medicine & Public Health Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq in women with advanced stage ovarian cancer
Basel, 13 July 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMagyn050 study showed that the addition of Tecentriq® (atezolizumab) to Avastin® (bevacizumab), paclitaxel and carboplatin did not meet its primary endpoint of progression-free survival (PFS) for the front-line treatment of women with newly diagnosed advanced stage ovarian cancer. Topline safety data indicate that safety for Tecentriq in combination with Avastin, paclitaxel and carboplatin was consistent with the known safety profile of the combination.“Ovarian cancer remains one of the most aggressive cancers a...
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

New compounds from starfish of Kuril basin show efficacy against cancer cells.
(Far Eastern Federal University) Russian scientists from Far Eastern Federal University (FEFU), G. B. Elyakov Pacific Institute of Bioorganic Chemistry (PIBOC FEB RAS), and A.V. Zhirmunsky National Scientific Center for Marine Biology (NSCMB FEB RAS) have discovered four new steroid substances which target cells of human breast cancer, and colorectal carcinoma. They were extracted from the starfish Ceramaster patagonicus, a Kuril basin seabed dweller. A related article appears in Marine Drugs. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 26, 2020 Category: Cancer & Oncology Source Type: news

Preop MRI finds 11% more cancer in women with DCIS
Preoperative breast MRI finds 11% more cancer in women with ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Years later, DCIS tied to more imaging but not anxiety Who gets breast cancer treatment during a pandemic? Breast MRI works as presurgical tool 10-minute breast MRI scan beats DBT for invasive cancer Does imaging modality influence DCIS recurrence? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 24, 2020 Category: Radiology Source Type: news

Roche ’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
Basel, 18 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion031 study, evaluating Tecentriq® (atezolizumab) in combination with chemotherapy (Abraxane®, albumin-bound paclitaxel; nab-paclitaxel; followed by doxorubicin and cyclophosphamide) in comparison to placebo plus chem otherapy (including Abraxane), met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in pathological complete response (pCR) for the treatment of people with early triple-negative breast cancer (TNBC), regardless of PD-L1 expression.“Tripl...
Source: Roche Media News - June 18, 2020 Category: Pharmaceuticals Source Type: news

Increased Risk for Invasive Breast Cancer After DCIS Increased Risk for Invasive Breast Cancer After DCIS
A new analysis shows that any diagnosis of ductal carcinoma in situ is associated with a long-term risk of invasive breast cancer and that treatment lowers this risk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 4, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
Basel, 2 June 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma (HCC) who have not received p rior systemic therapy.“We’re excited that today’s approval of Tecentriq in combination with Avastin for unresectable or metastatic hepatocellular carcinoma brings a cancer immunotherapy option to people with this aggressive form of liver cancer,” said Levi Garraway, M.D., Ph....
Source: Roche Media News - June 2, 2020 Category: Pharmaceuticals Source Type: news

Very Early-Stage Breast Cancer Ups Long-Term Odds for Invasive Tumors: Study
FRIDAY, May 29, 2020 -- Women with cancerous cells in their milk ducts -- also known as DCIS -- are at a high risk for developing fatal breast cancer, British researchers report. DCIS is short for ductal carcinoma in situ, an early form of breast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 29, 2020 Category: General Medicine Source Type: news

Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
(NRG Oncology) The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

Risk for Later Invasive Breast Cancer Up for Women With DCIS
THURSDAY, May 28, 2020 -- Women with screening-detected ductal carcinoma in situ (DCIS) have increased long-term risks for invasive breast cancer and breast cancer death, according to a study published online May 27 in The BMJ. Gurdeep S. Mannu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 28, 2020 Category: Pharmaceuticals Source Type: news

Years later, DCIS tied to more imaging but not anxiety
In the five years after treatment, women with a history of ductal carcinoma...Read more on AuntMinnie.comRelated Reading: Who gets breast cancer treatment during a pandemic? Sentinel lymph node biopsy unnecessary for DCIS Does imaging modality influence DCIS recurrence? Preop breast MRI improves DCIS surgical planning (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - May 26, 2020 Category: Radiology Source Type: news

How to Think About Your Cancer Care in the Time of COVID-19
Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment. Don’t panic. In the vast majority of cases, a diagnosis of cancer is not an emergency even though it feels like one. There is time to learn about your options and sort out what is right for you. For now, there will be changes to how we do things. Some of the changes will feel disruptive, but many will lead to better, more patient-centered care. Minimizing your chances of exposure to the virus doesn&rs...
Source: TIME: Health - April 28, 2020 Category: Consumer Health News Authors: Dr. Laura Esserman Tags: Uncategorized COVID-19 Source Type: news

Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies
Breast and mammary epithelial cells experience different local environments during tissue development and tumorigenesis. Microenvironmental heterogeneity gives rise to distinct cell regulatory states whose identity and importance are just beginning to be appreciated. Cellular states diversify when clonal three-dimensional (3D) spheroids are cultured in basement membrane, and one such state is associated with stress tolerance and poor response to anticancer therapeutics. Here, we found that this state was jointly coordinated by the NRF2 and p53 pathways, which were costabilized by spontaneous oxidative stress within 3D cult...
Source: Signal Transduction Knowledge Environment - April 13, 2020 Category: Science Authors: Pereira, E. J., Burns, J. S., Lee, C. Y., Marohl, T., Calderon, D., Wang, L., Atkins, K. A., Wang, C.-C., Janes, K. A. Tags: STKE Research Articles Source Type: news

Breast Cancer Survivor Advises Getting Mammograms Once Coronavirus Threat Ends
BOSTON (CBS) — Julie Tolek remembers the exact minute her life changed forever: June 26, 2019. It was eight in the morning when she was diagnosed with breast cancer. “I thought I was in a dream. Nightmare, I guess, is a better description,” Tolek recalled. “I couldn’t say the word. It couldn’t be my life.” The diagnosis: stage two grade two invasive ductal carcinoma — an aggressively growing cancer. “I chose to have a double mastectomy even though my cancer was only in one breast. I decided I wanted to do everything in my power to not have to go through this again,&rdqu...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 3, 2020 Category: Consumer Health News Authors: Health – CBS Boston Tags: Boston News Health Syndicated Local Breast Cancer Coronavirus Juli McDonald Mammograms Source Type: news